Loading stock analysis…
Evidence Synthesis
Last synthesized: 21 Oct 2026, 03:21
See how this stock's evidence score moved across recent sessions — unlock Pro for the live chart.
Full momentum history unlocks with Pro or Research.
Evidence velocity
Rate-of-change signals for this ticker unlock with Pro — or view flagship demos TCS / RELIANCE.
Evidence Synthesis
DELPHIFX's financial health has deteriorated, with -23.19 per share in Q2 2026, down from -10.51 in Q2 2025.
Revenue growth has stagnated, reaching 1.23 billion INR, a 12.5% decrease from Q2 2025. The company's market value has declined by 2.51 billion INR, representing a 5.1% drop from its 2025 peak. Despite efforts to diversify, DELPHIFX's sector classification remains unchanged, underscoring the need for a strategic overhaul.
Cite this
Source: Samhati evidence synthesis for DELPHIFX (2026-10-21). Observation: DELPHIFX's financial health has deteriorated, with -23.19 per share in Q2 2026, down from -10.51 in Q2 2025. Evidence quality: degraded. Not investment advice — no buy, sell, or hold recommendation. Full narrative (Pro): https://samhati.ai/pricing Page: https://samhati.ai/stock/delphifx